Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 3/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | FABP3 | P05413 | 2/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12248238 | 0.83 | ALOX12 (0.41) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL23902040 | 0.81 | ALDH1A1 (0.39) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL15035948 | 0.80 | LMNA (0.54) | ALOX12GAALMNATRPA1CHRM1 | |
| SCHEMBL23901705 | 0.79 | ALDH1A1 (0.38) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL12593462 | 0.78 | LMNA (0.54) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL15614475 | 0.77 | ALOX12 (0.59) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL17831097 | 0.77 | GABRA1 (0.39) | ALDH1A1LMNATRPA1GABRA1CHRM1 | |
| SCHEMBL7484629 | 0.77 | ALDH1A1 (0.53) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL15984530 | 0.77 | CRHR1 (0.41) | CRHR1ALDH1A1ALOX12HTTGAA | |
| SCHEMBL18929949 | 0.77 | RECQL (0.34) | LMNATRPA1CHRM1SLC6A2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
| US-10934295-B2 | Antimicrobials and methods of making and using same | BioVersys AG (CH) | 2021-03-02 | — | — | US | disclosed |
| US-20190211018-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | RIB-X PHARMACEUTICALS, INC. | 2019-07-11 | — | — | US | disclosed |
| WO-2017193023-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | MELINTA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9540372-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-01-10 | — | — | US | disclosed |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-9155737-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | disclosed |
| US-8912191-B2 | Pyrido[2,3-B]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-12-16 | — | — | US | disclosed |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2014-05-01 | — | — | US | disclosed |
| US-8546387-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-10-01 | — | — | US | disclosed |
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-09-20 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238568-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | CRHR1 2187/4885ALDH1A1 1655/4885ALOX12 2877/4885 |
| US-20150182526-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | CRHR1 2187/4885ALDH1A1 1655/4885ALOX12 2877/4885 |
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | CRHR1 3212/4885ALDH1A1 4745/4885ALOX12 2292/4885 |
| US-10934295-B2 | Antimicrobials and methods of making and using same | LPO, MPO, OAT | CRHR1 2272/4885ALDH1A1 1224/4885ALOX12 144/4885 |
| US-20160002230-A1 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE | BRAF, NRAS, RAF1 | CRHR1 2187/4885ALDH1A1 1655/4885ALOX12 2877/4885 |
| US-20140121212-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | CRHR1 2187/4885ALDH1A1 1655/4885ALOX12 2877/4885 |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | CRHR1 2187/4885ALDH1A1 1655/4885ALOX12 2877/4885 |
| US-20190211018-A1 | ANTIMICROBIALS AND METHODS OF MAKING AND USING SAME | LPO, MPO, OAT | CRHR1 2272/4885ALDH1A1 1224/4885ALOX12 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.